Press Release Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Jul 23
Press Release Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions Jul 16
Press Release Lilly to present Alzheimer’s disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment Jul 9